We are a COVID-19 Testing Facility
This is a Phase 3 research study looking into the effectiveness and safety of a new investigational medication (itepekimab). We want to find out if it can help reduce the number of flare-ups (also known as exacerbations) that people with COPD have over the course of a year.
Itepekimab is a human monoclonal antibody (a type of protein) that blocks the activity of
interleukin-33 (IL-33) in your body (interleukins are proteins that stimulate the immune
response and can cause inflammation).
IL-33 may play a role in COPD, and blocking the effects of IL-33 may improve COPD symptoms.
To date, itepekimab has been studied in 7 studies (tests) in humans: 5 completed studies
and 2 ongoing studies. Of the 5 completed studies:
A placebo is something that looks identical to the treatment that’s being investigated but doesn’t contain any active medication. The reason we give some participants a placebo is so we can compare the results of people who’ve taken tozorakimab with other people who’ve been through exactly the same process. It helps us ensure that any results we measure in this clinical trial are due to tozorakimab and not for any other reason.
You’ll be given the investigational medication (itepekimab) or placebo as an injection under the skin. The injection may be in your arm, abdomen, or thigh.
As well as questionnaires to track your COPD symptoms, you’ll have a few other tests done throughout the trial. These include breathing tests, blood tests, a CT scan or chest x-ray, and an ECG to check your heart.
This study will compensate each participant $100.00 for every completed study visit until the end of the study or withdrawal.
Being involved in our clinical trial won’t cost you anything. All trial-related costs above your usual care will be free. And don’t let travel costs put you off – we’re happy to talk about covering any expenses you need to take part in the study.
